PowerUp Acquisition Corp.
PWUPU
NASDAQ Global Market11.93
USD
+0.23
- -
CIK
0001847345
ISIN
KYG7207P1110
CUSIP
G7207P111
Return %
Stock
S&P500
1Y
9.55
24.99
3Y
19.18
70.19
5Y
19.18
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Surendra K. Ajjarapu
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 188 Grand Street New York City NY United States of America 10013
- IPO Date
- Feb 18, 2022
- CIK
- 0001847345
- Website
- powerupacq.com
- Similar Companies
- Business
- PowerUp Acquisition Corp. (NASDAQ: PWUPU) operates as a blank check company, or special purpose acquisition company (SPAC), with no significant ongoing operations other than pursuing a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more target businesses; it originally targets companies in the video gaming, gaming adjacent, and metaverse sectors without limitation to specific industries or geographies. The company offers SPAC units comprising one Class A ordinary share and one-half of one redeemable warrant, along with related Class A ordinary shares and warrants traded separately under tickers PWUP and PWUPW. Incorporated in 2021 and headquartered in New York, New York, PowerUp Acquisition Corp. completed a business combination with Aspire Biopharma, Inc. on February 17, 2025, resulting in its acquisition by the biopharmaceutical firm focused on novel drug delivery technologies such as fast-absorbing aspirin formulations like Instaprin™ for cardiac emergencies and pain management. Following the transaction closing, PowerUp's units were suspended from trading effective February 20, 2025, while the combined entity's common stock and warrants transitioned to new symbols ASBP and ASBPW on Nasdaq Global Market and Nasdaq Capital Market, respectively, with redomiciliation to Delaware. The deal, initially announced August 30, 2024, and stockholder-approved January 31, 2025, valued Aspire at a pre-money equity value of approximately $316 million and supports expanded product development and strategic growth in nutraceuticals, supplements, and FDA-approved drugs via patented sublingual absorption mechanisms.